Global Congenital Anosmia Treatment Market, By Treatment (Therapies and Medications), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Congenital Anosmia Treatment Market Analysis and Size
The global congenital anosmia treatment market is expected to witness significant growth during the forecast period. Anosmia mainly occurs in the middle aged and elderly; affecting up to 5% of people over the age of 45 years. The occurrence of congenital condition is rare with a prevalence of 1 in 10,000. The increasing need for an accurate and appropriate diagnosis for these conditions is expected to significantly impact the market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global congenital anosmia treatment market in the forecast period 2022-2029. The expected CAGR of global congenital anosmia treatment market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 1 billion in 2021, and it would grow upto USD 1.92 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Congenital anosmia is a condition in which people are born with the inability to smell for life. It may occur as an isolated abnormality or with a specific genetic disorder. People with no family history of the disease mostly suffer from isolated congenital anosmia. This diseased condition is increasing and thus it is very important to the healthcare sector.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Therapies and Medications), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Akorn Incorporated (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Sandoz International GmbH (Germany)
|
|
Market Opportunities
|
|
Global Congenital Anosmia Treatment Market Dynamics
Drivers
- Increase in Geriatric Population
According to the WHO, the elderly population was almost 524 million in 2010 and is expected to reach 1.5 billion by 2050. Additionally, the world has increasing geriatric population , especially in the developed countries such as the U.S., Germany, and Japan. Thus, it acts as a major driver in the market growth.
- Increasing Awareness of Healthcare Infrastructure
Another significant factor influencing the growth rate of global congenital anosmia treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
Opportunities
- Increase in Diabetes
Diabetes is one of the most common chronic conditions that is affecting millions of people globally. The rising sedentary lifestyles and lack of proper diet have been the major reasons for increase in prevalence of diabetes. The global prevalence of diabetes was around 9.3% in 2019 and is expected to reach 10.2% by 2030. It leaves a great impact on the growth of this market.
- Increase in the number of research and development activities
The market growth is fueled by an increase in the number of R&D activities and will provide beneficial opportunities for the global congenital amosmia treatment market. Major market players are focusing on the development of novel products for the treatment of anosmia, which is expected to boost the market growth in the mentioned forecast period. For instance, Zydus Cadila received the U.S. FDA approval in July 2020, for its supplemental abbreviated new drug application (SANDA) for Doxycycline Injection USP. It is expected to improve respiratory symptoms and anosmia
Restraints/Challenges
- Lack of Awareness
The sales of potential products are not succeeding much due to the less awareness of the syndrome. Though there are effective treatments which are available, but beliefs, poor inadequate communication between clinicians and patients, treatment adherence are the factors hindering the market growth.
- High Cost
The huge expenditure required for the treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This global congenital anosmia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global congenital anosmia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Congenital Anosmia Treatment Market
COVID-19 left a major impact on every business, and its long-term consequences are expected to influence industry growth during the forecast period.
The load on healthcare facilities and professionals was growing in tandem with the rapid increase in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the congenital anosmia treatment market. The epidemic has put a strain on the treatment procedures overall. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.
Global Congenital Anosmia Treatment Market Scope
The global congenital anosmia treatment market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
End-User
- Hospitals
- Research Institutes
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Congenital Anosmia Treatment Market Regional Analysis/Insights
The global congenital anosmia treatment market is analysed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.
The major countries covered in the global schaaf-yang syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the prevalence of the disease.
Asia-Pacific is considered to have the most lucrative period due to increasing number of patient population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Congenital Anosmia Treatment Market Share Analysis
The global congenital anosmia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global congenital anosmia treatment market
Key players operating in the global congenital anosmia treatment market include:
- Akorn Incorporated (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Prestige Consumer Healthcare Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Sandoz International GmbH (Germany)
SKU-